Hydroxychloroquine Sulfate Edest Intas Third Party Sales 2005

Hydroxychloroquine Sulfate, the active ingredient in Hydroxychloroquine Sulfate Edest Intas Third Party Sales 2005, is an antimalarial presented as an oral dosage form for oral use. It is employed in the prevention and treatment of malaria and as an immunomodulatory agent for rheumatoid arthritis and systemic lupus erythematosus.

GNH USA supplies Hydroxychloroquine Sulfate Edest Intas Third Party Sales 2005 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hydroxychloroquine Sulfate is used in the antimalarial and antirheumatic therapeutic pathways. - Malaria: prevents infection and treats acute episodes by targeting Plasmodium parasites. - Rheumatoid arthritis: reduces joint inflammation and disease activity through immune modulation. - Systemic lupus erythematosus: decreases disease flares and organ involvement by modulating immune response.

Hydroxychloroquine Sulfate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools. - Headache: transient cranial pain. - Skin rash: mild erythema or itching. - Visual disturbance: blurred vision or difficulty focusing.

Serious or Rare Side Effects: - Retinal toxicity: irreversible vision loss with prolonged use. - Cardiac arrhythmia: QT prolongation and potential torsades de pointes. - Severe hypoglycemia: especially in diabetic patients. - Hemolytic anemia: in individuals with G6PD deficiency. - Neuropsychiatric effects: agitation, depression, or psychosis.

When prescribing Hydroxychloroquine Sulfate, clinicians should consider several safety precautions. - Pregnancy: Category D; use only if benefits outweigh risks. - G6PD deficiency: risk of hemolysis; assess before therapy. - Retinal monitoring: baseline and periodic eye exams recommended. - Cardiac risk: avoid in patients with known QT prolongation or concomitant QT‑prolonging drugs. - Drug interactions: review concomitant medications for potential major interactions. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Hydroxychloroquine Sulfate interacts with several medicines that can alter its safety or efficacy.

Major Interactions (Avoid): - Azithromycin: combined QT prolongation risk. - Quinidine: additive cardiac conduction effects. - Digoxin: increased serum levels. - Cyclosporine: heightened toxicity risk. - Rifampin: reduces hydroxychloroquine concentrations.

Moderate Interactions (Monitor Closely): - Antacids (aluminum or magnesium): may decrease absorption. - Beta‑blockers: potential additive bradycardia. - Insulin or oral hypoglycemics: enhanced hypoglycemic effect. - NSAIDs: increased risk of renal impairment. - Warfarin: possible alteration of INR.